PNC-27 (5mg)

PNC-27 is a synthetic peptide initially developed for its proposed inhibitive action on cancer cell proliferation. It is a member of the PNC family of probe proteins and is designed to attach to malformed cancer cells and induce cell necrosis, but bypass normal functioning cells. The PNC-27 peptide contains the HDM2 binding domain and transmembrane domain corresponding to residue 1226 on p53. Researchers suggest that it exhibits potential to bind to and kill cancer cells through membrane lysis or cell membrane destruction. Research studies have suggested that the PNC-27 peptide may be selective in targeting specific cancer cell types, prompting further research within the context of pancreatic cancer, breast cancer, leukemia, melanoma, and other cancer strains.^[1]

The PNC protein was first developed in 2000. The PNC-27 peptide appears to be a non-toxic compound, attaching to and puncturing the membranes of individual cancer cells. As a result, rapid implosion may occur, leading to immediate cell death due to differences in osmotic pressure inside and outside the tumor cells. PNC-27 appears to have this potential through an affinity for binding to a protein called HDM2. Cancer cells typically display HDM2 in their cell membranes.^[2] According to the researchers “PNC-27 targets HDM-2 in the membranes of cancer cells, allowing it to induce membranolysis of these cells selectively.” Immediately after exposure to the PNC-27 peptide, studies have observed that the peptide appears to move to HDM2. Binding to them creates pores or holes in the cell membrane, causing “membrane lysis” or death of the cell membrane. This process, in turn, may lead to the destruction of cancer cells. Research is ongoing.